Limitations of Veterinary Clinical Trials

 

Evidence limitations are inherent to the design, conduct, reporting, and interpretation of veterinary clinical trials across species and settings.

Evidence Position Summary

​

• Veterinary clinical trials frequently involve small sample sizes, heterogeneous populations, and constrained recruitment, reducing statistical power and internal validity.

• Structural, ethical, regulatory, and funding differences distinguish veterinary trials from human clinical research and shape methodological limitations.

• Reporting quality, outcome selection, and sponsorship influence the interpretability and reproducibility of findings.

• Observational designs and owner-reported outcomes introduce bias distinct from controlled experimental trials.

• Translational assumptions between species, models, and clinical contexts introduce additional uncertainty.

What This Evidence Page Covers

 

This evidence page synthesizes peer-reviewed literature examining methodological, ethical, regulatory, and practical limitations of veterinary clinical trials. Coverage includes controlled and uncontrolled study designs, companion and food-animal contexts, infrastructure constraints, reporting quality, translational challenges, and gaps in interpretation between results and clinical application.

Evidence Breakdown

 

Study Design and Statistical Constraints

 

Small sample sizes remain a defining limitation of veterinary clinical trials, driven by recruitment challenges, disease prevalence, cost, and owner consent requirements. Underpowered studies reduce the precision of effect estimates and increase the risk of type I and type II errors, particularly in randomized controlled trials with multiple endpoints or in subgroup analyses (Weese et al., 2025; Wang et al., 2025).

 

Noninferiority and equivalence designs introduce additional interpretive complexity when margins lack biological justification or statistical justification within veterinary populations (Freise et al., 2013).

 

Recruitment, Infrastructure, and Feasibility

 

Veterinary trials rely heavily on client-owned animals, voluntary participation, and institutional infrastructure that varies widely across regions and practice types. Surveys of veterinary institutions identify limited staffing, inconsistent data systems, and fragmented trial networks as persistent constraints (Moore et al., 2021).

 

Practitioner attitudes, owner perceptions, and ethical concerns influence enrollment and retention, particularly in chronic disease and oncology trials (Gruen et al., 2017; Furtado et al., 2025).

 

Bias, Sponsorship, and Outcome Selection

 

Industry sponsorship correlates with differences in sample size justification, number of outcome measures, and reporting quality in veterinary randomized controlled trials (Wareham et al., 2017a; Wareham et al., 2017b).

 

Selective outcome reporting and inconsistent use of validated outcome measures limit comparability across studies, particularly in pain, behavior, and quality-of-life research (Sargeant et al., 2021; Mills, 2022).

 

Reporting Quality and Transparency

 

Analyses of veterinary trial publications identify incomplete reporting of randomization, blinding, sample size calculations, and adverse events. These deficiencies complicate replication and secondary evidence synthesis (Lund et al., 1998; Block, 2024).

 

Editorial and methodological commentaries highlight persistent gaps between published results and actionable interpretation, even in well-conducted trials (Boswood, 2017; Dean, 2017).

 

Ethical, Regulatory, and Oversight Limitations

 

Veterinary trials operate under heterogeneous regulatory frameworks across jurisdictions and species, which influence protocol approval, monitoring, and publication standards (Saliy et al., 2020; Baneux et al., 2014).

 

Ethical review processes for privately owned animals impose constraints distinct from those in laboratory animal research and human trials, particularly regarding informed consent, risk tolerance, and endpoint selection (Bertout et al., 2021; Page et al., 2016).

 

Translational and Comparative Limitations

 

Comparative and translational research assumes relevance across species and disease models, yet biological divergence, outcome relevance, and exposure differences limit extrapolation. Reviews of animal and veterinary models highlight misalignment between experimental conditions and clinical reality (Fürdös et al., 2015; Martinez et al., 2025; Van Norman, 2020).

 

Observational approaches, including target trial emulation using clinical records, address feasibility gaps yet retain confounding and data quality limitations inherent to non-randomized designs (Pegram et al., 2023).